Imunoterapia de primeira linha versus Quimioterapia em MSI-H/dMMR Câncer Colorectal Metastático: Revisão Sistemática e Meta-Análise de Estudos de Fase III
GastroenterologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- Journal of gastrointestinal cancer
- Publicado em
- 20 jul 2026
- Citações
- 1
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies
Wala Ben Kridis, Afef Khanfir
Descritores MeSH
- Immunotherapy
- Colorectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Immune Checkpoint Inhibitors
- Clinical Trials, Phase III as Topic
- Microsatellite Instability
- DNA Mismatch Repair
- Humans
- Randomized Controlled Trials as Topic
- Proto-Oncogene Proteins p21(ras)
Veja também
Estudos relacionados
- Efficacy and risk analysis of monotherapy and dual immunotherapy in dMMR/MSI-H metastatic colorectal cancer: a meta-analysis based on randomized controlled trials
- Discordance between radiological and pathological response to neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancer: a meta-analysis
- The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis
- First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial